Future research should prioritize long-term randomized placebo-controlled trials with larger sample sizes to provide stronger evidence on the long-term efficacy and safety of semaglutide for obesity treatment in PWS as well as explore the potential synergistic effects of GLP-1 RA treatment combined with other therapeutic interventions. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.